DIAGNOSIS: GLIOBLASTOMA MULTIFORME AND WHAT IS NEXT?

Glioblastoma multiforme is the most frequent and the most aggressive primary malignant tumor of the central nervous system. Despite of the progress that has been made in therapy of many solid tumors the gold standard of glioblastoma multiforme multimodal treatment has not changed for many years. The results from clinical trials have been remained disappointing. Therefore, treatment of this tumor has been challenge for neurosurgeons, neuro-oncologists and radiation oncologists. In this paper risk factors, prognostic/predictive factors, new directions of the innovative therapeutic options in glioblastoma multiforme were discussed. Additionally, complementary strategies and treatment of elderly patients were analyzed.

Autorentext

Aneta L. Zygulska, PhD, MD, studierte an der Jagiellonen-Universität, Polen. Sie ist Spezialistin für klinische Onkologie und onkologische Strahlentherapie. Sie hat in der Abteilung für Onkologie des Universitätskrankenhauses in Krakau, Polen, gearbeitet. Sie ist Autorin von Artikeln über pathophysiologische Mechanismen in der Onkologie und über die neurologische Toxizität von Krebstherapien.